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Background. Scaffolds for bone tissue engineering (BTE) can be loaded with stem and progenitor cells (SPC) from different sources
to improve osteogenesis. SPC can be found in bone marrow, adipose tissue, and other tissues. Little is known about osteogenic
potential of adipose-derived culture expanded, adherent cells (A-CEAC).This study compares in vivo osteogenic capacity between
A-CEAC and bone marrow derived culture expanded, adherent cells (BM-CEAC).Method. A-CEAC and BM-CEAC were isolated
from five female sheep and seeded on hydroxyapatite granules prior to subcutaneous implantation in immunodeficient mice. The
doses of cells in the implants were 0.5 × 106, 1.0 × 106, or 1.5 × 106 A-CEAC and 0.5 × 106 BM-CEAC, respectively. After eight weeks,
bone volume versus total tissue volume (BV/TV) was quantified using histomorphometry. Origin of new bone was assessed using
human vimentin (HVIM) antibody staining. Results. BM-CEAC yielded significantly higher BV/TV than any A-CEAC group, and
differences between A-CEAC groups were not statistically significant. HVIM antibody stain was successfully used to identify sheep
cells in this model. Conclusion. A-CEAC and BM-CEACwere capable of forming bone, and BM-CEAC yielded significantly higher
BV/TV than any A-CEAC group. In vitro treatment to enhance osteogenic capacity of A-CEAC is suggested for further research in
ovine bone tissue engineering.
1. Introduction
In orthopaedic and craniofacial surgery, reconstructing bone
defects from trauma, tumours, infection, loose prosthetic
components, or surgical procedures presents a medical chal-
lenge. Bone defects have traditionally been treated with
bone grafts to aid healing, the current gold standard being
iliac crest autograft [1]. The autograft is osteoconductive,
osteoinductive, and osteogenic but is associated with limited
supply and donor site morbidity [1]. Allograft is available as
cancellous or cortical graft or demineralized bone matrix. It
is osteoconductive and osteoinductive and available in large
quantities and is not associated with donor site morbidity.
However, allograft is not osteogenic and it carries the risk
of disease transmission. The shortcomings of autografts and
allografts have motivated the development of bone substi-
tutes [1–3]. Bone substitutes consist of a scaffold, usually
containing calcium or other minerals [4]. Scaffolds can be
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loaded with cytokines and cells to improve osteogenesis and
angiogenesis [5, 6].
Osteogenic cells (osteocytes and osteoblasts) originate
from SPC that reside in the tissue [7]. MSC are a subset of
SPC that are plastic-adherent in culture, can be differentiated
into tissue of different lineages, and are positive for markers
CD105, CD73, and CD90 and negative for CD45, CD34,
CD14 or CD11b, CD79𝛼 or CD19, and HLA-DR [8]. As
MSC can undergo differentiation into tissues unrelated to
the tissue in which they originally reside, MSC from one
tissuemay be useful in another, andMSC for bone substitutes
need not to originate from bone and could potentially be
harvested from adipose tissue [7, 9]. In contrast to bone
marrow, adipose tissue is easier to retrieve and can often be
harvested in abundant quantities, A-CEAC show lower levels
of senescence and can be expanded to higher passages in
vitro compared to BM-CEAC [10–12]. This makes adipose
tissue an appealing alternative to bone marrow as a source
of SPC for bone substitutes, provided that A-CEAC have
osteogenic capacity similar to or better than BM-CEAC.
Many studies investigate different scaffolds for A-CEAC;
however, the number of studies comparing A-CEAC to BM-
CEAC with respect to in vivo bone formation capacity is very
low and varies in species, cells used, characterizationmethod,
scaffold, model, and quantitative assessment, thus making
direct comparison difficult [13, 14]. BM-CEAC are currently
used in clinical settings [15].
The sheep is a frequently used model for orthopaedic
research for several reasons: the bone size is large enough
to perform complex orthopaedic procedures and for testing
medical devices and biomaterials; the lifespan is short enough
to perform age-related studies in diseases such as osteoarthri-
tis and osteoporosis [16]; and their bone remodelling is
comparable to that of humans [17]. Very little is known
about A-CEAC for BTE. To our knowledge, only one study
has compared ovine A-CEAC to BM-CEAC with respect to
in vivo bone formation; furthermore, the comparison was
performed in an orthotopic environment [18]. Ovine A-
CEAC and BM-CEAC have not yet been compared regarding
ectopic bone formation to assess the intrinsic osteogenic
capacity, so this would bring new information about ovine
A-CEAC.
This study aimed to investigate A-CEAC osteogenesis
using BM-CEAC osteogenesis as baseline. The objectives
of this study were to use a subcutaneous immunodeficient
mouse model [19] to (1) assess the efficacy of A-CEAC on
bone formation, (2) compare bone formation between ovine
A-CEAC and BM-CEAC, and (3) compare bone formation
between different doses of A-CEAC to see if seeding A-CEAC
closer improves osteogenesis. Furthermore, we investigate
whether a marker for human vimentin (HVIM) can be used
to identify ovine cells in implants and thus to reveal the origin
of the cells.
We hypothesize that A-CEAC can form new bone in
this model, that A-CEAC can form new bone at the same
BV/TV as BM-CEAC, that seeding A-CEAC closer improves
osteogenesis, and that HVIM can be used to identify sheep
cells in histomorphometry.
Table 1: Animal and implant groups. Cells were seeded on 40mg
HA scaffold as previously described [19].
Mouse group Pouch mg HAgranules Cells Denoted
1 (𝑛 = 7)
Upper left 40 0.5 × 10
6
BM-CEAC BM-CEAC
Lower left 40 0.5 × 10
6
BM-CEAC BM-CEAC
Upper right 40 0.5 × 10
6
A-CEAC A-CEAC1
Lower right 40 0.5 × 10
6
A-CEAC A-CEAC1
2 (𝑛 = 7)
Upper left 40 1.0 × 10
6
A-CEAC A-CEAC2
Lower left 40 1.0 × 10
6
A-CEAC A-CEAC2
Upper right 40 1.5 × 10
6
A-CEAC A-CEAC3
Lower right 40 1.5 × 10
6
A-CEAC A-CEAC3
2. Materials and Methods
2.1. Study Design. A-CEAC and BM-CEAC were isolated
from ovine adipose tissue or iliac crest aspirate, culture
expanded, and seeded on hydroxyapatite (HA) granules.
Mice were divided into two groups. In mouse group 1,
granules seeded with 0.5 × 106 BM-CEAC (denoted BM-
CEAC) were implanted in the left pouches, and granules
seeded with 0.5 × 106 A-CEAC (denoted A-CEAC1) were
implanted in the right pouches. In mouse group 2, granules
were seeded with 1.0 × 106 A-CEAC (denoted A-CEAC2) for
the left pouches and 1.5 × 106 A-CEAC (denoted A-CEAC3)
for the right pouches. Mice and implant groups are shown in
Table 1. The workflow is outlined in Figure 1.
2.2. Animals. Five female sheep (Texel/Gotland breed, 2–7
years of age) were acquired as donor sheep two months prior
to surgery for acclimatization.
Fourteen immunodeficient (NOD.CB17-Prkdcscid/J)mice
(7-8 weeks of age) were acquired from Charles River, Saint-
Germain-sur-l’Arbresle, France, one week before surgery.
They had free access to sterilized feed (Altromin 1342
Rat/Mouse, Brogaarden, Lynge, Denmark) and water.
This study was approved by the Danish Animal Exper-
iments Inspectorate (2012-15-2934-00704) and followed
national and institutional guidelines.
2.3. A-CEAC Isolation and Expansion. Subcutaneous fatty
tissue was excised from left lumbar side of sheep. Analgose-
dation was initialized with midazolam (B. Braun Medical,
Frederiksberg, Denmark) 1.0mg/kg i.v. and maintained with
ketamine (Intervet Danmark, Ballerup, Denmark) andmida-
zolam i.v. in an 8 : 1 ratio, and local anaesthesia was achieved
using 5mL lidocaine s.c. (Amgros, Copenhagen, Denmark).
A small incision was made through the skin, eight gram fatty
tissue was excised, and the incision was closed in layers.
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Figure 1: Study design. CEAC from adipose tissue (A-CEAC) and bone marrow (BM-CEAC) was isolated from 5 female sheep, expanded in
vitro, and seeded onto HA prior to subcutaneous implantation in immunodeficient mice. After 8 weeks, implants were harvested and bone
volume versus total tissue volume was assessed by histomorphometry. Each mouse received four implants as previously described [19].
A-CEAC isolation was done as previously described [20].
Briefly, fatty tissuewaswashed andminced extensively. Tissue
was digested with 0.35% Type II collagenase (Worthington,
UK) at 37∘C for 60min, washed twice, and filtered through a
100 𝜇m cell strainers to obtain a single cell suspension.
After red blood cell lysis, cells were cultured in DMEM
supplemented with 10% foetal bovine serum (FBS; Sigma-
Aldrich, Copenhagen,Denmark), 1% penicillin-streptomycin
(PS; Sigma-Aldrich), and 4mML-Glutamine (Lonza, Copen-
hagen, Denmark) for two passages and pooled.
2.4. BM-CEAC Isolation and Expansion. Bone marrow was
aspirated from iliac crest of donor sheep as previously
described [21]. The aspirate was density gradient centrifuged
using a Histopaque gradient (Sigma-Aldrich) to obtain
mononuclear cells and cultured in Gibco’s Alpha Minimal
EssentialMediumwith 10%FBS, 1%Penicillin-Streptomycin-
Glutamine, 1% 1M HEPES buffer, and 1% 100mM sodium
pyruvate (all Gibco products) for two passages. The cell
solutions were cryopreserved at −80∘C for one month until
scaffold preparation. Upon revival, cells were expanded as
described above for one passage and pooled.
2.5. Colony-FormingUnit Assay. Acolony-forming unit assay
(CFU-f) was performed to measure the prevalence of stem
and progenitor cells in the initial bone marrow aspirate
or adipose tissue sample [7]. One sample from each bone
marrow aspirate or adipose tissue stromal vascular fraction
was taken for the CFU-f assay just prior to culture expansion.
100,000 cells from bone marrow aspirate or 10,000 cells from
adipose stromal vascular fraction were seeded in T80 flasks,
medium was changed after 7 days, and CFU-f staining was
performed 3 days hereafter. Clusters with at least 50 cells were
considered colonies. For bone marrow CFU-f samples, all
colonies were counted. Adipose tissue CFU-f samples were
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counted by randomsampling of the assay surface and counted
using a grid.
2.6. Preparation of Scaffold. The day before mouse surgery,
cells were seeded onto scaffold granules in growth medium
in cut-off syringes as described previously [19]. Scaffolds were
HA granules with a diameter of 1.0–2.5mm (ENGIPORE,
Fin-Ceramica, Faenza, Italy) characterized by a high porosity
at up to 90% relative to the total volume.
Before seeding, cells were trypsinized and counted, and
the appropriate number of cells were suspended in 300𝜇L
growth medium and loaded onto sterile HA granules as
described [19]. The scaffolds were incubated for 24 hours
(37∘C, 5% CO2) before implantation.
2.7. Ectopic Mouse Model. Four implants were placed sub-
cutaneously in each mouse according to previous report
[19]. On the day of surgery, mice were anaesthetized
(100mg/kg ketamine (Ketaminol 10, Intervet, Ballerup, Den-
mark), 10mg/kg xylazine (Rompun Vet, Bayer, Germany),
and isoflurane (Baxter, Søborg, Denmark)), and scaffolds
were placed in pouches according to Table 1. Incisions were
closed and mice were kept separate for 7 days and then
housed together in groups of 3-4 until termination of study.
After 8 weeks of observation, mice were euthanized by
cervical dislocation, and implants were recovered and placed
in 4% neutral buffered formaldehyde for 48 hours.
2.8. Histology andHistomorphometry. Implants were decalci-
fied in 12.5% ethylenediaminetetraacetic acid (EDTA; Merck
Life Science, Hellerup, Denmark) for ten days and embedded
in paraffin. Three serial sections were cut 100, 200, and
300 𝜇m into the implant for a total of nine sections. Sec-
tions were deparaffinized, stained with haematoxylin-eosin
(HE), blinded, and evaluated in random order by the same
researcher. At each sectioning level, the two best sectionswere
analysed and averaged. The volume of bone (BV), fibrous
tissue (Fb.V), marrow (Ma.V), and remaining granules (Gr.V)
were quantified relative to total tissue volume (TV) using
stereological software (newCAST, Visiopharm, Denmark).
Additional sections from the middle level were stained
with HVIM (Thermo Scientific, clone SP20, cat.no RM-9120)
to detect ovine cells, as HVIM has shown cross-reaction with
ovine cells.
2.9. Statistical Analyses and Sample Size Calculation. Statisti-
cal analyses were performed using Stata 14 (StataCorp, Col-
lege Station, Texas, USA). For normality and homoscedastic-
ity, Shapiro-Wilk’s test and Levene’s test were used, respec-
tively. As our data is heteroscedastic, we used the Welch t-
test to assess pairwise difference between groups. To reduce
the risk of type I errors, significance level was reduced
using Bonferroni correction. Differences were considered
statistically significant at 𝑝 < 0.008 (corresponding to 𝑝 <
0.05 before Bonferroni correction for pairwise comparison of
4 groups).
Sample size for implants was calculated according to [22].
Accepted risk of error of first and second kinds was set to
5% and 20%, respectively. Minimal relevant difference was
set to 70%, and standard deviation was set to 58% based
on existing data [21]. This results in 𝑛 = 10.78, and thus
11 implants should be included in each group. Each mouse
carries 2 implants from 2 groups, so a total of 6 mice should
be included in each group. We included 7 mice in each group
due to risk of dropout and implant migration, giving a total
of 14 implants per group.
3. Results
The average CFU-f count from all sheep was 4.96% ± 9.52 for
stromal vascular fraction and 0.07% ± 0.02 for bone marrow
aspirate.
Some implants migrated and merged with another
implant during the observation period and were excluded.
Number of remaining implants was 10 in eachA-CEACgroup
and 14 in BM-CEAC group.
BV/TV, Fb.V/TV, Gr.V/TV, and Ma.V/TV are shown in
Figure 2. Significantly higher BV/TV was found in BM-
CEAC implants compared to A-CEAC groups. Compared
to A-CEAC groups, the BM-CEAC group contained at least
10 times higher BV/TV. Between A-CEAC groups, 0.5 ×
106 A-CEAC contained slightly higher BV/TV than the
other A-CEAC groups; however, this difference was not
statistically significant. In all samples, the present bone
tissue was observed adjacent to scaffolds. In samples with
lower BV/TV, fibrous tissue dominated the areas adjacent
to residual granules. All histological samples except one
from A-CEAC3 group showed signs of ossification and
vascularization. Gr.V/TV did not differ. BM-CEAC group
contained higher Ma.V/TV, both as red and yellow marrow.
Representative sample specimens are shown in Figure 3 (A-
CEAC1 in Figure 3(a), A-CEAC2 in Figure 3(b), A-CEAC3 in
Figure 3(c), and BM-CEAC in Figure 3(d)).
A BM-CEAC sample (corresponding to Figure 3(d))
stained with HVIM is available in Figure 4. Samples from
skin (Figure 5(a)), muscle (Figure 5(b)), adipose tissue
(Figure 5(c)), and bone (Figure 5(d)) from a control mouse,
along with an implant without cells (Figure 5(e)) and an
implant with cells (Figure 5(f)) stained without primary
antibody, were all negative for HVIM. Negative samples are
shown in Figure 5. Residual scaffold was generally connected
to HVIM+ tissue (either bone or fibrous tissue), and no
HVIM+ tissue was found in areas without residual granules.
The implants as whole were encapsulated in HVIM− fibrous
tissue, muscle or adipose tissue, with branches reaching into
the implant, sometimes separating areas with HVIM+ tissue.
All bone tissues were infiltrated with HVIM+ cells, and all
osteocytes were HVIM+. Fibrous tissue was either HVIM+
orHVIM−. All areas ofmarrowwereHVIM−. HVIM+ tissue
was only found related to residual granules. AllHVIMstained
specimens were evaluated. We did not distinguish between
red and yellow marrow.
4. Discussion
We aimed at evaluating A-CEAC and BM-CEAC intrinsic
in vivo osteogenic capacity and chose not to perform any
in vitro differentiation prior to implantation. We chose the
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Figure 2: Amount of newly formed bone tissue (BV), fibrous tissue (Fb.V), residual granules (Gr.V), and bone marrow (Ma.V) relative to
total tissue volume (TV). A-CEAC1: 0.5 × 106 A-CEAC (𝑛 = 10); A-CEAC2: 1 × 106 A-CEAC (𝑛 = 10); A-CEAC3: 1.5 × 106 A-CEAC (𝑛 = 10);
BM-CEAC: 0.5 × 106 BM-CEAC (𝑛 = 14). ∗𝑝 < 0.002 corresponding to 𝑝 < 0.01 prior to Bonferroni correction.
gold standard for intrinsic osteogenic capacity and the ectopic
bone formationmodel over the orthotopicmodel to eliminate
possible bone formation from residing osteogenic cells [23].
This study demonstrates that it is possible to induce bone
formation using A-CEAC and BM-CEAC from sheep, that
BM-CEAC form significantly more bone than A-CEAC, that
seeding A-CEAC closer does not improve osteogenesis, and
additionally that antibody staining againstHVIMcan be used
to identify sheep cells in implants in mice.
The International Society for Cellular Therapy (ISCT)
suggested a set of minimal criteria to characterize MSC [8].
These criteria were not met in this study. The cells used
in this study were plastic-adherent but were not differen-
tiated to different lineages or sorted by surface markers.
Multilineage differentiation has been shown by others using
similar isolation techniques [18], and surface markers were
not considered relevant, as surface antibodies for the relevant
surface antigens have not yet been validated for sheep. The
cells used in this study, referenced as A-CEAC and BM-
CEAC, were culture expanded and obtained using a similar
protocol to obtainMSC [24–26]. Regarding cell characteriza-
tion criteria in other studies comparing intrinsic osteogenic
capacity between A-CEAC and BM-CEAC (see Table 1),
all use adherence, most use CD105+, CD90+, CD45−, and
CD34−, only a fewuse differentiation, and none fulfil the total
MSC criteria as defined by ISCT [8]. This shows a lack of
standardization and qualitative and quantitative assessment
in the literature, making direct comparison between studies
difficult.
Though BM-CEAC formed significantly more bone than
A-CEAC, some bone was present in all A-CEAC implants but
one from A-CEAC3 group. Scattered across A-CEAC spec-
imens, several areas characterized by lower cell density and
stronger eosin stain than fibrous tissue were found (see centre
of Figure 3(a)). These areas were considered fibrous tissue in
this analysis and did not qualify as bone tissue. It seems likely
that these areas were undergoing mineralization at termina-
tion of the study, and a prolonged observation period may
yield more bone [27]. However, to what extent a prolonged
observation period affects osteogenesis is unknown.
Difference between BV/TV across A-CEAC groups was
not significant. A slightly lower BV/TV was observed in
A-CEAC2 and A-CEAC3 groups compared to A-CEAC1.
An initial investigation into this difference would seek to
identify the number of cells attached to granules prior to
implantation. In this study, cells were seeded on granules with
the assumption that all cells would adhere to the granules, and
this assumption has not been verified.
We did not include an empty (cell-free) control group
in this study. Our laboratory has previously shown that
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(a) (b)
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BMa
O
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Gr
(d)
Figure 3: Representative images from A-CEAC1 (a), A-CEAC2 (b), A-CEAC3 (c), and BM-CEAC (d) groups. B: bone; Gr: residual granules;
Fb: fibrous tissue; Ma: bone marrow; O: other. Scalebar: 250 𝜇m.
BMa O
Gr
Fbm
Fbo
Figure 4: HVIM stain. Tissue stained positive is of ovine origin. All
bone tissue in all samples is associated with HVIM+ cells. Fibrous
tissue is either HVIM+ or HVIM−. B: bone; Gr: residual granules;
Fbm: murine fibrous tissue; Fbo: ovine fibrous tissue; Ma: bone
marrow; O: other. Scalebar: 250 𝜇m.
empty controls contain less than 0.2% BV/TV using the same
scaffold and animal [21].Thus, a paired design with an empty
control in each mouse for per-mouse baseline osteogenesis—
or an empty group for overall baseline osteogenesis—would
have very little effect on the results presented here. Also,
osteocytes were HVIM+, and along with the negative panel
in Figure 5 all bone tissue was considered of ovine origin.
Some implants migrated and merged with another
implant and were excluded, and the number of implants
in A-CEAC groups is below our power calculation. While
dropout at this magnitude was not expected, we do not
believe fewer dropouts would move the results in a less
significant direction.
A number of studies have compared A-CEAC to BM-
CEAC with respect to bone formation (see Table 2). Ectopic
osteogenic capacity has been compared in 2 studies. Brocher
et al. compared human A-CEAC to BM-CEAC on tricalcium
phosphate subcutaneously in immunodeficient mice for 8
or 12 weeks. They observed new bone more frequently in
BM-CEAC specimens than A-CEAC specimens (significance
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(a) (b) (c)
(d) (e) (f)
Figure 5: Tissue samples from skin (a), muscle (b), adipose tissue (c), and bone (d), an implant without primary antibody (e), and an implant
without cells (f). All samples are HVIM−. Scalebar: 250 𝜇m.
not described), and they observed new bone in A-CEAC
specimens more frequently after 12 weeks than after 8 weeks
[27]. Hayashi et al. compared rat A-CEAC to BM-CEAC
on HA disks subcutaneously for 6 weeks and found that
BM-CEAC formed significantly more bone than A-CEAC
assessed on 𝜇CT [28]. Assessed on histology, Hayashi et al.
also observed new bone in all BM-CEAC specimens and
none in A-CEAC specimens.These two studies utilize similar
scaffolds and a subcutaneous environment comparable to the
current study, and both of these studies and the current study
show more bone formation from BM-CEAC than from A-
CEAC.
Orthotopic osteogenic capacity has also been compared
in a few studies. Jo et al. created a segmental femur defect
in rats and seeded human A-CEAC or BM-CEAC on an
HA/TCP cylinder for implantation [29]. After 12 weeks,
significantly higher BV/TV was observed with BM-CEAC
compared to A-CEAC assessed on 𝜇CT. Conventional X-
ray revealed no significant difference. Kang et al. created
a segmental radius defect in dogs and compared A-CEAC
and BM-CEAC on TCP scaffold for 20 weeks [31]. Neither
conventional X-ray nor histomorphometry showed signifi-
cant difference between groups. Niemeyer et al. created a
segmental tibia defect in sheep and compared A-CEAC to
BM-CEAConmineralized collagen scaffold for 26weeks [18].
Assessed by both conventional X-ray and histomorphometry,
A-CEAC were inferior to BM-CEAC on BV/TV. These three
segmental defectmodel studies all show that A-CEACmay be
inferior to BM-CEAC when comparing BV/TV. Miyazaki et
al. created a spinal fusionmodel in rats using humanA-CEAC
or BM-CEAC on a collagen sponge [33]. After 8 weeks, 𝜇CT
did not reveal a significant difference between A-CEAC and
BM-CEAC groups. Wen et al. used human A-CEAC or BM-
CEAC on collagen gel in a calvarial defect in rats [32]. After 8
weeks, no significant difference was found between A-CEAC
and BM-CEAC groups assessed by conventional X-ray. Taken
together, some evidence announce BM-CEAC superior to A-
CEAC regarding bone formation capacity, while others show
insignificant differences.
Compared to BM-CEAC, A-CEAC may be inferior in
bone formation due to (1) stronger commitment to nonbone
forming cell lineages or (2) inferior neovascularization prop-
erties. Stronger commitment to bone forming cell lineages
could be achieved through in vitro differentiation, prolonged
culturing on scaffold prior to implantation, and transfection
or by using cytokine releasing scaffolds. Using a scaffold with
functional groups resembling native extracellular matrixmay
provide a solution to both problems [34]. To clarify whether
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Table 2: Studies comparing A-CEAC and BM-CEAC without osteogenic gene transfection or differentiation prior to implantation. Only
data related to bone formation is shown. All studies used CEAC from 2nd to 5th passages. 𝑝 values shown when available. Adapted with
modifications from Liao and Chen [13].
Author Cellorigin Cell characterization Animal model Scaffold
Observation
time Analytic method Outcome
Brocher et
al. [27] Human
Adherence, CD105+,
CD73+, CD90+,
CD34−, CD45−
Subcutaneous in
mice TCP granules
8 weeks Histology (new bone
observed in
specimens)
A-CEAC: 0/22
BM-CEAC: 11/14
12 weeks A-CEAC 2/6BM-CEAC 5/6
Hayashi et
al. [28] Rat
Adherence, CD90+,
CD29+, CD45− Subcutaneous HA disk 6 weeks
𝜇CT (bone volume)
A-CEACa 0.05mm3±
0.05
BM-CEAC
6.85mm3± 1.89 (𝑝 <
0.001)
Histology (new bone
observed in
specimens)
A-CEAC: none
BM-CEAC: all
Jo et al. [29] Human
Adherence, CD105+,
CD73+, CD90+,
CD34−, CD45−,
HLA-DR-
Segmental
femur defect in
rat
HA/TCP
(60%/40%)
cylinder
12 weeks
X-ray (bone
formation score
[30])
BM-CEACb: 4.00 ±
0.63
A-CEACb: 3.17 ± 0.75
(n.s.)
CT (BV/TV)
BM-CEAC: 14.2% ±
1.4
A-CEAC: 10.4% ± 1.2
(𝑝 < 0.05)
Kang et al.
[31] Dog
Adherence, CD73+,
CD90+, CD44+,
CD34−, CD45−,
CD14−
Segmental
radius defect TCP/PLGC 20 weeks
X-ray (radiographic
healing)
BM-CEACc: 7/8
A-CEACc: 6/8
Histomorphometry
(BV/TV)
A-CEAC: 33.90% ±
4.31
BM-CEAC: 33.56% ±
8.09 (n.s.)
Liao and
Chen [13] Human Adherence
Spinal fusion in
rats
Collagen
sponge 8 weeks
𝜇CT (BV/TV)
Insignificant
difference between
A-CEACd and
BM-CEACd
Histology
(description)
No bridging observed
in A-CEAC or
BM-CEAC groups
Niemeyer et
al. [18] Sheep
Adherence,
differentiation into
bone/cartilage/fat
Segmental tibia
defect
Mineralized
collagen type
I
26 weeks
X-ray (relative bone
area in defect)
A-CEAC inferior to
BM-CEAC
(𝑝 < 0.05)e
Histomorphometry
(BV/TV)
A-CEAC inferior to
BM-CEAC (𝑝 < 0.01)
Wen et al.
[32] Human
Adherence CD105+,
CD90+, CD29+,
CD44+, CD34−,
differentiation into
bone/fat
Calvarial defect
in rats Collagen gel 8 weeks
X-ray (average grey
level)
Insignificant
difference between
A-CEAC and
BM-CEAC
This study Sheep Adherence Subcutaneous inmice HA granules 8 weeks
Histomorphometry
(BV/TV)
A-CEAC: 1.78% ±
0.91
BM-CEAC: 20.87% ±
3.70 (𝑝 < 0.0017)f
aA-CEAC from pellet shown here, bundifferentiated groups shown here, ctime to healing was not significant, dtransfected with LacZ reporter gene; data
available only in figure, edata available only in figure, and f𝑝 value corresponds to 𝑝 < 0.01 prior to Bonferroni correction.
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sheep A-CEAC can be applied in bone substitutes, further
investigations in the enhancement of the osteogenic capacity
of A-CEAC are needed.
These results do not translate to a clinical setting for
several reasons.This study was designed to answer a research
question related to basic science, and thus both species and
sample size need to be changed to make it translatable to
humans. Some differences in osteogenic capacity between
human and rhesus monkeys have been shown, and differ-
ences between human and sheep have, to our knowledge, not
yet been investigated [35].
5. Conclusion
A-CEAC seeded on HA granules yielded significantly lower
BV/TV than BM-CEAC after eight weeks subcutaneously
in immunodeficient mice. This may be due to stronger
commitment of A-CEAC to nonbone forming cell lines than
BM-CEAC. A-CEAC at a concentration of 0.5 × 106 cells
yielded slightly higher BV/TV thanA-CEAC at 1.0× 106 or 1.5
× 106, though this difference was not statistically significant.
Human vimentin antibody stain was successfully used to
identify ovine cells in our implants. As such, ovine cells do not
need pretreatmentwith labelling techniques for identification
in implants in thismodel. BothA-CEACandBM-CEACwere
capable of forming bone, and bone tissue was found in all
histology samples but one from 1.5 × 106 A-CEAC group.
Though A-CEACwere capable of forming new bone, some in
vitro treatment to enhance osteogenic capacity is suggested
for further research in ovine bone tissue engineering.
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